Original Publication Date: 1 January, 2015
Publication / Source: Immunotherapy
Authors: Navid Hafez & Daniel P Petrylak
Highlighting this years’ American Society for Clinical Oncology (ASCO) conference were presentations focusing on T-cell immune checkpoint blockade as a therapeutic target in solid tumors. Promising results in melanoma, lung and renal cancers have led to further disease-specific Phase I and II trials of immune checkpoint blockade in other solid tumors refractory to treatment.